Regulatory milestones in focus

GENinCode PLC (LSE:GENI), the predictive genetics company focused on cardiovascular disease, published its half-year financial report on 29 September 2026, following an announcement on 28 August 2026 of milestone clinical results for its CARDIO inCode-Score test. The company's investment case continues to hinge on securing US regulatory approval for that test. Earlier in the year, it said it planned to file an updated submission with the US Food and Drug Administration in the third quarter of 2026, targeting approval by the end of the following quarter.

What the company does

GENinCode develops genetic risk assessment tests that combine genetic information with clinical data to predict the risk of cardiovascular disease. Its main product, CARDIO inCode-Score, is designed to help clinicians identify patients at higher risk of coronary heart disease. The company sells in the UK, Europe and the US, and has also explored applications in ovarian cancer surveillance. In December 2025 it announced approval of CARDIO inCode-Score in New York State.

Latest developments

Full-year results for 2025, released on 8 June 2026, showed revenue up 14% to £3.1m from £2.7m, driven by volume growth in the UK, US and Europe. Gross margin improved to 59% from 53%. However, the pre-tax loss widened to £5.9m from £5.1m as administrative expenses rose to £6.7m, reflecting commercial selling costs and lower R&D tax credits. The adjusted EBITDA loss increased to £4.9m from £4.4m.

The company said revenue for the first four months of 2026 was broadly in line with the same period of 2025, despite lower income from the NHS and a pilot study in Catalonia. It said commercial discussions with Thermo Fisher Scientific on pricing and distribution of CARDIO inCode were continuing, alongside strategic talks with the NHS on heart disease prevention and ovarian cancer surveillance. Chief executive Matthew Walls said the company anticipated continued growth and commercial updates.

Financial picture

Year-end cash was £0.8m, down from £1.1m a year earlier, and the company subsequently raised £4.7m after the year end. Reports on the day of the full-year results said the shares fell 18.26% to 0.94p. For 2026, the company has guided to year-on-year revenue growth and improved margins, with EBITDA losses narrowing towards breakeven. GENinCode does not pay a dividend. Following the half-year report released on 29 September, the second-half trajectory against that guidance remains the key question for shareholders assessing the company's progress.

Sector and index context

Genetic risk testing is a growing field, but adoption depends on regulatory approvals, reimbursement and acceptance by health systems. The US market is particularly important because of its scale, which is why the FDA process carries such weight. Within the FTSE AIM All Share Index, GENinCode is a small healthcare technology company whose valuation reflects the binary nature of regulatory outcomes.

Key risks

The most immediate risk is regulatory: the FDA has previously asked for additional data, and further delays would postpone US commercialisation. The company is loss-making and has relied on share raises, so more dilution is possible. Dependence on NHS budgets and partnership negotiations adds uncertainty to revenue growth.

What to watch next

Investors will look for confirmation that the updated FDA submission has been filed and for any response from the regulator. Progress in the Thermo Fisher discussions, NHS contracts and the trajectory of revenue and cash in the second half of 2026 will also be closely watched, ahead of full-year results for 2026.